Aberantni imunofenotipovi u prognozi akutne mijeloične leukemije

Aim: Diagnosis of acute myeloid leukemia (AML) is based on cytomorphological, immunophenotypic and cytogenetic findings. The main role of immunophenotyping is lineage assignement and detection of aberrant phenotypes. The objective of this study was to analyze the incidence and the prognostic value of aberrant phenotypes in AML. Methods: Data on diagnosis and treatment of 123 patients with newly diagnosed AML, treated in the University Hospital Center Zagreb in the period from 2000-2007, was retrospectively analyzed. Results: The incidence of aberrant phenotypes was 74.8 %. The most frequent aberrant phenotype was asynchronous expression which was found in 70 % of patients, followed by co-expression of lymphoid markers in 35 % of patients and loss of lineage-specific markers in 24 % of patients. The aberrant phenotype CD33-CD13+ correlates with lower complete remission rate, while the aberrant phenotype CD117+C34+CD15+/CD14+/CD11b+ correlates with shorter overall and disease-free survival. Discussion and conclusion: In addition to its diagnostic role, immunophenotyping of AML offers information about patient prognosis through the detection of aberrant phenotypes.